Current Edition

gene-editing

Intellia, expanding in gene editing, buys startup Rewrite for $45M

Dive Brief: Intellia Therapeutics, a leading developer of CRISPR-based medicines, on Thursday said it will buy privately held Rewrite Therapeutics for $45 million, as it …

Continue Reading →